O	0	3	The	The	DT	B-NP
O	4	16	contribution	contribution	NN	I-NP
O	17	19	of	of	IN	B-PP
O	20	26	Harold	Harold	NNP	B-NP
O	27	28	F	F	NNP	I-NP
O	28	29	.	.	.	I-NP
O	30	36	Dvorak	Dvorak	NNP	I-NP
O	37	39	to	to	TO	B-PP
O	40	43	the	the	DT	B-NP
O	44	49	study	study	NN	I-NP
O	50	52	of	of	IN	B-PP
B-Cancer	53	58	tumor	tumor	NN	B-NP
O	59	71	angiogenesis	angiogenesis	NN	I-NP
O	72	75	and	and	CC	O
B-Tissue	76	82	stroma	stroma	NN	B-NP
O	83	93	generation	generation	NN	I-NP
O	94	104	mechanisms	mechanism	NNS	I-NP
O	104	105	.	.	.	O

O	106	108	In	In	IN	B-PP
O	109	113	1983	1983	CD	B-NP
O	113	114	,	,	,	O
O	115	121	Harold	Harold	NNP	B-NP
O	122	128	Dvorak	Dvorak	NNP	I-NP
O	129	132	and	and	CC	O
O	133	136	his	his	PRP$	B-NP
O	137	147	colleagues	colleague	NNS	I-NP
O	148	152	were	be	VBD	B-VP
O	153	156	the	the	DT	B-NP
O	157	162	first	first	JJ	I-NP
O	163	165	to	to	TO	B-VP
O	166	170	show	show	VB	I-VP
O	171	175	that	that	IN	B-SBAR
B-Cell	176	181	tumor	tumor	NN	B-NP
I-Cell	182	187	cells	cell	NNS	I-NP
O	188	196	secreted	secrete	VBD	B-VP
O	197	205	vascular	vascular	JJ	B-NP
O	206	218	permeability	permeability	NN	I-NP
O	219	225	factor	factor	NN	I-NP
O	226	227	(	(	(	O
O	227	230	VPF	VPF	NN	B-NP
O	230	231	)	)	)	O
O	232	235	and	and	CC	O
O	236	240	that	that	IN	B-SBAR
O	241	242	a	a	DT	B-NP
O	243	251	blocking	block	VBG	I-NP
O	252	260	antibody	antibody	NN	I-NP
O	261	263	to	to	TO	B-PP
O	264	267	VPF	VPF	NN	B-NP
O	268	273	could	could	MD	B-VP
O	274	281	prevent	prevent	VB	I-VP
O	282	285	the	the	DT	B-NP
B-Pathological_formation	286	291	edema	edema	NN	I-NP
O	292	295	and	and	CC	I-NP
B-Organism_substance	296	301	fluid	fluid	NN	I-NP
O	302	314	accumulation	accumulation	NN	I-NP
O	315	319	that	that	WDT	B-NP
O	320	322	is	be	VBZ	B-VP
O	323	337	characteristic	characteristic	JJ	B-ADJP
O	338	340	of	of	IN	B-PP
O	341	346	human	human	JJ	B-NP
B-Cancer	347	354	cancers	cancer	NNS	I-NP
O	354	355	.	.	.	O

O	356	358	In	In	IN	B-PP
O	359	363	1986	1986	CD	B-NP
O	363	364	,	,	,	O
O	365	371	Dvorak	Dvorak	NNP	B-NP
O	372	376	went	go	VBD	B-VP
O	377	379	on	on	IN	B-PP
O	380	382	to	to	TO	B-VP
O	383	394	demonstrate	demonstrate	VB	I-VP
O	395	399	that	that	IN	B-SBAR
O	400	403	VPF	VPF	NN	B-NP
O	404	407	was	be	VBD	B-VP
O	408	416	secreted	secrete	VBN	I-VP
O	417	419	by	by	IN	B-PP
O	420	421	a	a	DT	B-NP
O	422	429	variety	variety	NN	I-NP
O	430	432	of	of	IN	B-PP
O	433	438	human	human	JJ	B-NP
B-Cell	439	444	tumor	tumor	NN	I-NP
I-Cell	445	449	cell	cell	NN	I-NP
I-Cell	450	455	lines	line	NNS	I-NP
O	456	459	and	and	CC	O
O	460	468	proposed	propose	VBD	B-VP
O	469	473	that	that	IN	B-SBAR
O	474	477	VPF	VPF	NN	B-NP
O	478	481	was	be	VBD	B-VP
O	482	484	in	in	IN	B-PP
O	485	489	part	part	NN	B-NP
O	490	501	responsible	responsible	JJ	B-ADJP
O	502	505	for	for	IN	B-PP
O	506	509	the	the	DT	B-NP
O	510	518	abnormal	abnormal	JJ	I-NP
B-Multi-tissue_structure	519	530	vasculature	vasculature	NN	I-NP
O	531	535	seen	see	VBN	B-VP
O	536	538	in	in	IN	B-PP
O	539	544	human	human	JJ	B-NP
B-Cancer	545	551	tumors	tumor	NNS	I-NP
O	551	552	.	.	.	O

O	553	555	As	As	IN	B-PP
O	556	557	a	a	DT	B-NP
O	558	564	result	result	NN	I-NP
O	564	565	,	,	,	O
O	566	568	he	he	PRP	B-NP
O	569	572	and	and	CC	O
O	573	578	other	other	JJ	B-NP
O	579	592	investigators	investigator	NNS	I-NP
O	593	605	demonstrated	demonstrate	VBD	B-VP
O	606	610	that	that	IN	B-SBAR
O	611	614	VPF	VPF	NN	B-NP
O	615	618	was	be	VBD	B-VP
O	619	626	capable	capable	JJ	B-ADJP
O	627	629	of	of	IN	B-PP
O	630	641	stimulating	stimulate	VBG	B-VP
B-Cell	642	653	endothelial	endothelial	JJ	B-NP
I-Cell	654	658	cell	cell	NN	I-NP
O	659	665	growth	growth	NN	I-NP
O	666	669	and	and	CC	I-NP
O	670	682	angiogenesis	angiogenesis	NN	I-NP
O	682	683	.	.	.	O

O	684	689	These	These	DT	B-NP
O	690	701	fundamental	fundamental	JJ	I-NP
O	702	713	discoveries	discovery	NNS	I-NP
O	714	717	led	lead	VBD	B-VP
O	718	720	to	to	TO	B-PP
O	721	731	additional	additional	JJ	B-NP
O	732	740	research	research	NN	I-NP
O	741	750	conducted	conduct	VBN	B-VP
O	751	753	by	by	IN	B-PP
O	754	763	Napoleone	Napoleone	NNP	B-NP
O	764	771	Ferrara	Ferrara	NNP	I-NP
O	772	775	and	and	CC	O
O	776	779	his	his	PRP$	B-NP
O	780	790	laboratory	laboratory	NN	I-NP
O	790	791	,	,	,	O
O	792	802	confirming	confirm	VBG	B-VP
O	803	806	the	the	DT	B-NP
O	807	814	cloning	cloning	NN	I-NP
O	815	817	of	of	IN	B-PP
O	818	821	VPF	VPF	NN	B-NP
O	822	825	and	and	CC	O
O	826	834	renaming	rename	VBG	B-VP
O	835	838	the	the	DT	B-NP
O	839	846	protein	protein	NN	I-NP
O	847	855	vascular	vascular	JJ	I-NP
O	856	867	endothelial	endothelial	JJ	I-NP
O	868	874	growth	growth	NN	I-NP
O	875	881	factor	factor	NN	I-NP
O	882	883	(	(	(	O
O	883	887	VEGF	VEGF	NN	B-NP
O	887	888	)	)	)	O
O	888	889	.	.	.	O

O	890	892	In	In	IN	B-PP
O	893	897	1986	1986	CD	B-NP
O	897	898	,	,	,	O
O	899	905	Dvorak	Dvorak	NNP	B-NP
O	906	914	proposed	propose	VBD	B-VP
O	915	919	that	that	IN	B-SBAR
O	920	922	by	by	IN	B-PP
O	923	932	secreting	secrete	VBG	B-VP
O	933	936	VPF	VPF	NN	B-NP
O	936	937	,	,	,	O
B-Cancer	938	944	tumors	tumor	NNS	B-NP
O	945	951	induce	induce	VBP	B-VP
O	952	964	angiogenesis	angiogenesis	NN	B-NP
O	965	967	by	by	IN	B-PP
O	968	975	turning	turn	VBG	B-VP
O	976	978	on	on	IN	B-PP
O	979	982	the	the	DT	B-NP
B-Pathological_formation	983	988	wound	wound	NN	I-NP
O	989	996	healing	healing	NN	I-NP
O	997	1005	response	response	NN	I-NP
O	1005	1006	.	.	.	O

O	1007	1009	He	He	PRP	B-NP
O	1010	1015	noted	note	VBD	B-VP
O	1016	1020	that	that	IN	B-SBAR
B-Pathological_formation	1021	1027	wounds	wound	NNS	B-NP
O	1027	1028	,	,	,	O
O	1029	1033	like	like	IN	B-PP
B-Cancer	1034	1040	tumors	tumor	NNS	B-NP
O	1040	1041	,	,	,	O
O	1042	1049	secrete	secrete	JJ	B-NP
O	1050	1053	VPF	VPF	NN	I-NP
O	1053	1054	,	,	,	O
O	1055	1062	causing	cause	VBG	B-VP
B-Multi-tissue_structure	1063	1068	blood	blood	NN	B-NP
I-Multi-tissue_structure	1069	1076	vessels	vessel	NNS	I-NP
O	1077	1079	to	to	TO	B-VP
O	1080	1084	leak	leak	VB	I-VP
B-Organism_substance	1085	1091	plasma	plasma	NN	B-NP
O	1092	1102	fibrinogen	fibrinogen	NN	I-NP
O	1102	1103	,	,	,	O
O	1104	1109	which	which	WDT	B-NP
O	1110	1120	stimulates	stimulate	VBZ	B-VP
B-Multi-tissue_structure	1121	1126	blood	blood	NN	B-NP
I-Multi-tissue_structure	1127	1133	vessel	vessel	NN	I-NP
O	1134	1140	growth	growth	NN	I-NP
O	1141	1144	and	and	CC	O
O	1145	1153	provides	provide	VBZ	B-VP
O	1154	1155	a	a	DT	B-NP
O	1156	1162	matrix	matrix	NN	I-NP
O	1163	1165	on	on	IN	B-PP
O	1166	1171	which	which	WDT	B-NP
O	1172	1176	they	they	PRP	B-NP
O	1177	1180	can	can	MD	B-VP
O	1181	1187	spread	spread	VB	I-VP
O	1187	1188	.	.	.	O

O	1189	1195	Unlike	Unlike	IN	B-PP
B-Pathological_formation	1196	1202	wounds	wound	NNS	B-NP
O	1202	1203	,	,	,	O
O	1204	1211	however	however	RB	B-ADVP
O	1211	1212	,	,	,	O
O	1213	1217	that	that	WDT	B-NP
O	1218	1222	turn	turn	VBP	B-VP
O	1223	1226	off	off	RP	B-PRT
O	1227	1230	VPF	VPF	NN	B-NP
O	1231	1241	production	production	NN	I-NP
O	1242	1247	after	after	IN	B-PP
O	1248	1255	healing	heal	VBG	B-VP
O	1255	1256	,	,	,	O
B-Cancer	1257	1263	tumors	tumor	NNS	B-NP
O	1264	1267	did	do	VBD	B-VP
O	1268	1271	not	not	RB	I-VP
O	1272	1276	turn	turn	VB	I-VP
O	1277	1280	off	off	RP	B-PRT
O	1281	1286	their	their	PRP$	B-NP
O	1287	1290	VPF	VPF	NN	I-NP
O	1291	1301	production	production	NN	I-NP
O	1302	1305	and	and	CC	O
O	1306	1313	instead	instead	RB	B-VP
O	1314	1323	continued	continue	VBD	I-VP
O	1324	1326	to	to	TO	I-VP
O	1327	1331	make	make	VB	I-VP
O	1332	1337	large	large	JJ	B-NP
O	1338	1345	amounts	amount	NNS	I-NP
O	1346	1348	of	of	IN	B-PP
O	1349	1352	VPF	VPF	NN	B-NP
O	1352	1353	,	,	,	O
O	1354	1362	allowing	allow	VBG	B-VP
B-Cell	1363	1372	malignant	malignant	JJ	B-NP
I-Cell	1373	1378	cells	cell	NNS	I-NP
O	1379	1381	to	to	TO	B-VP
O	1382	1390	continue	continue	VB	I-VP
O	1391	1393	to	to	TO	I-VP
O	1394	1400	induce	induce	VB	I-VP
O	1401	1404	new	new	JJ	B-NP
B-Multi-tissue_structure	1405	1410	blood	blood	NN	I-NP
I-Multi-tissue_structure	1411	1418	vessels	vessel	NNS	I-NP
O	1419	1422	and	and	CC	O
O	1423	1425	so	so	RB	B-ADVP
O	1426	1428	to	to	TO	B-VP
O	1429	1433	grow	grow	VB	I-VP
O	1434	1437	and	and	CC	I-VP
O	1438	1444	spread	spread	VB	I-VP
O	1444	1445	.	.	.	O

O	1446	1450	Thus	Thus	RB	B-ADVP
O	1450	1451	,	,	,	O
B-Cancer	1452	1458	tumors	tumor	NNS	B-NP
O	1459	1465	behave	behave	VBP	B-VP
O	1466	1470	like	like	IN	B-PP
B-Pathological_formation	1471	1477	wounds	wound	NNS	B-NP
O	1478	1482	that	that	WDT	B-NP
O	1483	1487	fail	fail	VBP	B-VP
O	1488	1490	to	to	TO	I-VP
O	1491	1495	heal	heal	VB	I-VP
O	1495	1496	.	.	.	O

O	1497	1501	This	This	DT	B-NP
O	1502	1506	work	work	NN	I-NP
O	1507	1509	is	be	VBZ	B-VP
O	1510	1515	again	again	RB	B-ADVP
O	1516	1525	extremely	extremely	RB	B-ADJP
O	1526	1537	significant	significant	JJ	I-ADJP
O	1538	1541	for	for	IN	B-PP
O	1542	1550	patients	patient	NNS	B-NP
O	1551	1560	worldwide	worldwide	RB	B-ADVP
O	1560	1561	,	,	,	O
O	1562	1564	as	as	IN	B-SBAR
O	1565	1571	Dvorak	Dvorak	NNP	B-NP
O	1571	1572	'	'	POS	B-NP
O	1572	1573	s	s	JJ	I-NP
O	1574	1584	scientific	scientific	JJ	I-NP
O	1585	1593	research	research	NN	I-NP
O	1594	1596	is	be	VBZ	B-VP
O	1597	1604	leading	lead	VBG	I-VP
O	1605	1608	his	his	PRP$	B-NP
O	1609	1619	colleagues	colleague	NNS	I-NP
O	1620	1623	all	all	DT	B-ADVP
O	1624	1628	over	over	IN	B-PP
O	1629	1632	the	the	DT	B-NP
O	1633	1638	world	world	NN	I-NP
O	1639	1641	to	to	TO	B-VP
O	1642	1649	examine	examine	VB	I-VP
O	1650	1653	how	how	WRB	B-ADVP
O	1654	1656	to	to	TO	B-VP
O	1657	1662	treat	treat	VB	I-VP
O	1663	1664	a	a	DT	B-NP
B-Cancer	1665	1670	tumor	tumor	NN	I-NP
O	1671	1678	through	through	IN	B-PP
O	1679	1682	its	its	PRP$	B-NP
B-Organism_substance	1683	1688	blood	blood	NN	I-NP
O	1689	1695	supply	supply	NN	I-NP
O	1695	1696	.	.	.	O

